Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — Gold Coast Investment Showcase 2022
16 slides from Neuroscientific Biopharmaceuticals's conference presentation, Jun 22, 2022
Slide 1: NeuroScientific to present at Gold Coast Investment Showcase
ASX ANNOUNCEMENT 22 June 2022 NEUROSCIENTIFIC TO PRESENT AT GOLD COAST INVESTMENT For personal use only SHOWCASE NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) (“NeuroScientific” or “the company”) is pleased to advise shareholders and investors that CEO and Managing Director Matt Liddelow will be
Slide 2: Novel Drug Therapies for Neurodegenerative Conditions
For personal use only NOVEL DRUG THERAPIES FOR NEURODEGENERATIVE CONDITIONS COMPANY PRESENTATION JUNE 2022 • ASX: NSB neuroscientific.com
Slide 3: Disclaimer
DISCLAIMER For personal use only The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex
Slide 4: Company Highlights
COMPANY HIGHLIGHTS For personal use only DEVELOPING NOVEL EMTINBTM: LEAD DRUG CLINICAL DEVELOPMENT PEPTIDE-BASED CANDIDATE WITH COMMENCING IN 1H CY2022 THERAPEUTIC DISEASE MODIFYING DRUGS POTENTIAL Developing peptide-based A first-in-class treatment for HREC approval has been drugs with disease modi
Slide 5: Corporate Overview
CORPORATE OVERVIEW For personal use only CAPITAL STRUCTURE SHARE PRICE CHART NSB $0.17 143.5m 16.8m ASX Code Share price Shares on Unlisted (20/06/22) issue options $25m $7.3m 48% Market Net cash Top 20 capitalisation position shareholders BOARD & MANAGEMENT Paul Rennie Matt Liddelow Dr Anton Uvarov
Slide 6: Addressing Global Unmet Medical Need in Neurodegenerative Conditions
ADDRESSING GLOBAL UNMET MEDICAL NEED IN NEURODEGENERATIVE CONDITIONS For personal use only The underlying cause of most neurodegenerative conditions is not known 40M $27B 70M Developing a solution is Patients Market value Incidence of worldwide Glaucoma challenging when the cause is not fully unders
Slide 7: EmtinB: Lead Drug Candidate with Disease Modifying Potential
EMTINBTM: LEAD DRUG CANDIDATE WITH DISEASE MODIFYING POTENTIAL For personal use only EmtinBTM promotes cell survival and regeneration, and reduces inflammation in neurodegenerative conditions EMTINBTM MODELLED ON HUMAN PROTECTIVE PROTEIN MT-II EMTINBTM TARGETS LRP-1 • Advanced peptide • LRP-1 recept
Slide 8: EmtinB Disease Modifying Effect in Alzheimer's Disease
EMTINBTM DISEASE MODIFYING EFFECT IN ALZHEIMER’S DISEASE For personal use only ALZHEIMER’S DISEASE – PREVENTING COGNITIVE DECLINE AD MOUSE MODEL Validated in the gold- standard animal model Cognition: treatment for 48 days Protected tissue of the EmtinB 70% +7 brain and improved memory Control 38% +
Slide 9: EmtinB Disease Modifying Effect in Multiple Sclerosis
EMTINBTM DISEASE MODIFYING EFFECT IN MULTIPLE SCLEROSIS For personal use only MULTIPLE SCLEROSIS – POTENTIAL TO TREAT ALL STAGES EFFECT OF EMTINBTM: EFFECT OF EMTINBTM: % INCREASE IN OLIGODENDROCYTES Increased the PRELIMINARY RESULTS FROM ANIMAL STUDY Mature OGCs 875% number of myelin- Lowered clini
Slide 10: EmtinB Disease Modifying Effect in Glaucoma
EMTINBTM DISEASE MODIFYING EFFECT IN GLAUCOMA For personal use only GLAUCOMA – PROTECTING THE OPTIC NERVE AND PREVENTING VISION LOSS NOT TREATED EMTINB TREATED Performed in pig model; structure of the eye very similar Lamina cribrosa to humans Prevented damage to retinal cells Post- lamina cribrosa
Slide 11: EmtinB Development Overview
EMTINBTM – DEVELOPMENT OVERVIEW For personal use only INDICATION RESEARCH SAFETY & TOX CLINICAL DEVELOPMENT ALZHEIMER’S DISEASE 1H CY2022 NERUOLOGY The same safety & toxicology data from the MULTIPLE SCLEROSIS indication above will be used to support MS OPHTHALMOLOGY GLAUCOMA 2H CY2022 ISCHEMIC NEUR
Slide 12: Partnering with Leading Research Organisations
PARTNERING WITH LEADING RESEARCH ORGANISATIONS For personal use only NON-CLINICAL CLINICAL RESEARCH RESEARCH neuroscientific.com • 11
Slide 13: Transitioning to Clinical Development
TRANSITIONING TO CLINICAL DEVELOPMENT For personal use only NSB is EARLY- progressing PHASE I EmtinBTM EmtinBTM PHASE CLINICAL EmtinBTM into CLINICAL TRIAL clinical trials in TRIAL 1H CY2022 REGULATORY DISCOVERY PRECLINICAL PHASE I PHASE II PHASE III REVIEW & RESEARCH TOXICOLOGY CLINICAL TRIAL CLINI
Slide 14: Early-Stage Clinical Development Program
EARLY-STAGE CLINICAL DEVELOPMENT PROGRAM For personal use only EARLY-PHASE PHASE I CLINICAL CLINICAL TRIAL DE-RISKING LATE- TRIAL STAGE CLINICAL DEVELOPMENT 30 healthy volunteers Up to 80 healthy volunteers Development of pharmacodynamic (PD) Assessment of safety and tolerability of biomarkers to co
Slide 15: Pivotal Milestones
PIVOTAL MILESTONES KEY MILESTONES COMPLETED For personal use only SAFETY & TOXICITY STUDIES IN ANIMALS (NEUROLOGY INDICATIONS) PRECLINICAL BIOMARKER PROGRAM – IDENTIFIED POTENTIAL PD & EFFICACY BIOMARKERS MANUFACTURING OF CLINICAL-GRADE (GMP) EMTINB™ HREC APPROVAL TO COMMENCE EARLY-PHASE CLINICAL TR
Slide 16: For more information contact
For personal use only neuroscientific.com For more information contact: Matt Liddelow – CEO & Managing Director E: ml@neuroscientific.com
NeuroScientific Biopharmaceuticals — Gold Coast Investment Showcase 2022 on 6ix